The Importance of Biomarker Data Management

August 13, 2020 — Cell therapy clinical trials typically generate a significant quantity and diversity of biologic data intended to characterize disease and patient biology, as well as data intended to demonstrate evidence of therapeutic mechanisms. QuartzBio’s Cliff Culver et al., explores the benefits of capturing and integrating molecular biomarker data within clinical trials to build foundations for data assets. Read the article in the latest issue of Applied Clinical Trials Magazine.

Click here to view the article

Author: Cliff Culver | Senior Vice President | QuartzBio, part of Precision for Medicine

Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.

QUARTZBIO® and the PRECISION QUARTZBIO logo® are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved. The names and logos of other companies and products appearing on the website may be trademarks or registered trademarks of such other companies.